EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

Alba Cervantes González, Alejandra O Morcillo-Nieto, Sara Serrano, Bessy Benejam, Laura Videla, Isabel Barroeta, Susana Fernández, Laura Del Hoyo Soriano, Aida S Hernandez, Lucía Maure-Blesa, Lídia Vaqué-Alcázar, Javier Arranz und 12 weitere

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Alba Cervantes González und 23 weiteren Autor:innen. Beteiligte Einrichtung: Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, beta-Synuclein. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, NIA NIH HHS, Departament de Salut, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION There is a need for early, objective markers of Alzheimer's disease (AD)‐related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β‐synuclein is elevated in the blood of adults with DS. This study evaluates the positioning of these changes relative to changes in pathophysiological blood biomarkers along the AD continuum. METHODS We quantified serum β‐synuclein using immunoprecipitation–mass spectrometry in a cross‐sectional cohort ( n = 131) spanning the AD continuum in adults with DS ( n = 88) and cognitively unimpaired euploid controls ( n = 43). RESULTS β‐synuclein levels were elevated in individuals with DS ( p < 0.001), preceding symptom onset by two decades and changes in other blood biomarkers (tau phosphorylated at threonine 217, neurofilament light, glial fibrillary acidic protein) by several years. Higher β‐synuclein was associated with cortical atrophy ( p < 0.001) and hypometabolism ( p < 0.001) in AD‐vulnerable regions and reduced episodic memory ( p < 0.009). DISCUSSION These findings consolidate β‐synuclein as an early blood‐based biomarker of synaptic dysfunction and provide insight into early AD‐related mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeAlzheimer Diseasebeta-SynucleinHumansFemaleBiomarkersMaleCross-Sectional StudiesMiddle AgedAdulttau ProteinsNeurofilament ProteinsGlial Fibrillary Acidic ProteinAgedBrain

Stichwörter der Autor:innen

Alzheimer's diseaseDown syndromebeta‐synucleinblood biomarkers

Substanzen

Biomarkersbeta-Synucleintau ProteinsNeurofilament ProteinsGlial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain.
  • Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

ORCID-Profile: Olivia Belbin

Förderung

  • Deutsche Forschungsgemeinschaft
  • NIA NIH HHS
  • Departament de Salut, Generalitat de Catalunya
  • Instituto de Salud Carlos III
  • Alzheimer's Association
  • Bundesministerium für Forschung und Technologie
  • ALS Association
  • HORIZON EUROPE Health

Zitieren

APA

Cervantes González, A., Morcillo-Nieto, A. O., Serrano, S., Benejam, B., Videla, L., Barroeta, I., Fernández, S., Del Hoyo Soriano, L., Hernandez, A. S., Maure-Blesa, L., Vaqué-Alcázar, L., Arranz, J., Rodríguez-Baz, Í., Aranha, M. R., Perlaza, D., Lidón, L., Alcolea, D., Bejanin, A., Carmona-Iragui, M., …, & Belbin, O. (2026). Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71860

Vancouver

Cervantes González A, Morcillo-Nieto AO, Serrano S, Benejam B, Videla L, Barroeta I, et al. Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71860

BibTeX
@article{CervantesGonzlez2026,
  author = {Cervantes González, Alba and Morcillo-Nieto, Alejandra O and Serrano, Sara and Benejam, Bessy and Videla, Laura and Barroeta, Isabel and Fernández, Susana and Del Hoyo Soriano, Laura and Hernandez, Aida S and Maure-Blesa, Lucía and Vaqué-Alcázar, Lídia and Arranz, Javier and Rodríguez-Baz, Íñigo and Aranha, Mateus R and Perlaza, Danna and Lidón, Laia and Alcolea, Daniel and Bejanin, Alexandre and Carmona-Iragui, María and Fortea, Juan and Lleó, Alberto and Otto, Markus and Oeckl, Patrick and Belbin, Olivia},
  title = {Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71860}
}
Kostenlos starten →